Cellectar Biosciences, Inc.
CLRB$13M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaFLORHAM PARK11 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jun 22, 2026
9wMarket Overview
Stock performance and key metrics
CLRB News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Paclitaxel
Non Small Cell Lung Cancer
Patent 2034
NOV-002
Ovarian Cancer
NOV-205
Hepatitis C
Iopofosine I 131 single dose
Waldenstrom Macroglobulinemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Paclitaxel | Phase 3 | Non Small Cell Lung Cancer | - | Patent 2034 |
NOV-002 | Phase 3 | Ovarian Cancer | - | - |
NOV-205 | Phase 2 | Hepatitis C | - | - |
Iopofosine I 131 single dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Non Small Cell Lung Cancer
1 drug in this indication
Waldenstrom Macroglobulinemia
1 drug in this indication
Hepatitis C
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply